Trade Verrica Pharmaceuticals Inc. - VRCA CFD

Add to favourite

6.87

2.28%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data
Events
Income Statement
Balance Sheet
Cash Flow

Trading сonditions

Spread

0.07

Long position overnight fee

-0.026179%

Short position overnight fee

0.003957%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

Stock exchange

United States of America

Commission on trade

*Information provided by Capital.com

Verrica Pharmaceuticals Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats

Prev. Close*	7.03
Open*	6.88
1-Year Change*	9.38%
Day's Range*	6.76 - 6.94
52 wk Range	2.86-8.70
Average Volume (10 days)	222.50K
Average Volume (3 months)	23.24M
Market Cap	242.29M
P/E Ratio	-100.00K
Shares Outstanding	42.06M
Revenue	3.20M
EPS	-1.07
Dividend (Yield %)	N/A
Beta	1.92
Next Earnings Date	Feb 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 17, 2024	7.03	0.25	3.69%	6.78	7.10	6.76
Apr 16, 2024	6.96	0.23	3.42%	6.73	7.11	6.72
Apr 15, 2024	6.89	0.17	2.53%	6.72	6.92	6.64
Apr 12, 2024	6.85	0.01	0.15%	6.84	6.96	6.72
Apr 11, 2024	7.03	0.00	0.00%	7.03	7.15	6.83
Apr 10, 2024	7.14	0.31	4.54%	6.83	7.23	6.83
Apr 9, 2024	7.01	0.15	2.19%	6.86	7.21	6.86
Apr 8, 2024	6.97	0.24	3.57%	6.73	6.98	6.37
Apr 5, 2024	6.67	0.49	7.93%	6.18	6.72	6.18
Apr 4, 2024	6.38	0.40	6.69%	5.98	6.68	5.98
Apr 3, 2024	6.12	0.48	8.51%	5.64	6.15	5.64
Apr 2, 2024	5.85	0.28	5.03%	5.57	5.88	5.57
Apr 1, 2024	5.88	0.05	0.86%	5.83	5.98	5.55
Mar 28, 2024	5.87	0.21	3.71%	5.66	5.98	5.53
Mar 27, 2024	5.60	0.36	6.87%	5.24	5.68	5.18
Mar 26, 2024	5.30	0.55	11.58%	4.75	5.38	4.73
Mar 25, 2024	5.03	0.05	1.00%	4.98	5.12	4.84
Mar 22, 2024	4.98	0.08	1.63%	4.90	5.01	4.80
Mar 21, 2024	4.98	0.12	2.47%	4.86	5.04	4.80
Mar 20, 2024	4.92	0.34	7.42%	4.58	4.95	4.58

Verrica Pharmaceuticals Inc. Events

Time (UTC)	Country	Event
Tuesday, May 7, 2024
Time (UTC) 12:30	Country US	Event Q1 2024 Verrica Pharmaceuticals Inc Earnings Release Q1 2024 Verrica Pharmaceuticals Inc Earnings Release Forecast - Previous -
Friday, June 7, 2024
Time (UTC) 14:00	Country US	Event Verrica Pharmaceuticals Inc Annual Shareholders Meeting Verrica Pharmaceuticals Inc Annual Shareholders Meeting Forecast - Previous -
Tuesday, August 6, 2024
Time (UTC) 12:30	Country US	Event Q2 2024 Verrica Pharmaceuticals Inc Earnings Release Q2 2024 Verrica Pharmaceuticals Inc Earnings Release Forecast - Previous -

View all events

Annual
Quarterly

	2022	2021	2020	2019	2018
Total revenue	9.032	12	0	0	0
Revenue	9.032	12		0	0
Total Operating Expense	31.765	42.908	40.181	30.08	21.878
Selling/General/Admin. Expenses, Total	17.405	26.979	24.508	14.644	9.052
Research & Development	12.198	15.929	15.673	15.436	12.826
Operating Income	-22.733	-30.908	-40.181	-30.08	-21.878
Interest Income (Expense), Net Non-Operating	-1.696	-4.172	-2.512	1.877	1.231
Net Income Before Taxes	-24.487	-35.08	-42.694	-28.207	-20.648
Net Income After Taxes	-24.487	-35.08	-42.694	-28.207	-20.648
Net Income Before Extra. Items	-24.487	-35.08	-42.694	-28.207	-20.648
Net Income	-24.487	-35.08	-42.694	-28.207	-20.648
Income Available to Common Excl. Extra. Items	-24.487	-35.08	-42.694	-28.207	-20.648
Income Available to Common Incl. Extra. Items	-24.487	-35.08	-42.694	-28.207	-20.648
Diluted Net Income	-24.487	-35.08	-42.694	-28.207	-20.648
Diluted Weighted Average Shares	34.1634	27.0445	24.9956	24.8979	25.8099
Diluted EPS Excluding Extraordinary Items	-0.71676	-1.29712	-1.70806	-1.13291	-0.8
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS	-0.6747	-1.29712	-1.70806	-1.13291	-0.8
Other, Net	-0.058		-0.001	-0.004	-0.001
Total Adjustments to Net Income					0
Cost of Revenue, Total	0.725
Gross Profit	8.307
Unusual Expense (Income)	1.437

	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022
Total revenue	0.182	0.037	0.068	8.319	0.214
Revenue	0.182	0.037	0.068	8.319	0.214
Total Operating Expense	11.798	7.126	6.279	8.308	9.335
Selling/General/Admin. Expenses, Total	5.937	4.319	3.189	3.925	5.173
Research & Development	5.725	2.739	2.365	2.946	4.162
Operating Income	-11.616	-7.089	-6.211	0.011	-9.121
Interest Income (Expense), Net Non-Operating	0.626	0.5	0.286	0.067	-1.046
Net Income Before Taxes	-10.99	-6.589	-5.932	0.083	-10.168
Net Income After Taxes	-10.99	-6.589	-5.932	0.083	-10.168
Net Income Before Extra. Items	-10.99	-6.589	-5.932	0.083	-10.168
Net Income	-10.99	-6.589	-5.932	0.083	-10.168
Income Available to Common Excl. Extra. Items	-10.99	-6.589	-5.932	0.083	-10.168
Income Available to Common Incl. Extra. Items	-10.99	-6.589	-5.932	0.083	-10.168
Diluted Net Income	-10.99	-6.589	-5.932	0.083	-10.168
Diluted Weighted Average Shares	45.9169	43.0234	41.1702	44.6562	27.5191
Diluted EPS Excluding Extraordinary Items	-0.23935	-0.15315	-0.14408	0.00186	-0.36949
Dividends per Share - Common Stock Primary Issue	0	0		0	0
Diluted Normalized EPS	-0.23935	-0.15315	-0.14408	0.03404	-0.36949
Other, Net	0		-0.007	0.005	-0.001
Unusual Expense (Income)			0	1.437
Cost of Revenue, Total	0.136	0.068	0.725
Gross Profit	0.046	-0.031	-0.657

Annual
Quarterly

	2022	2021	2020	2019	2018
Total Current Assets	39.115	74.328	67.65	64.983	91.152
Cash and Short Term Investments	34.273	70.354	65.47	62.017	89.809
Cash & Equivalents	34.273	15.752	10.686	9.241	10.271
Prepaid Expenses	4.355	3.974	2.18	2.966	1.343
Total Assets	44.721	80.125	74.154	68.424	91.906
Total Current Liabilities	3.459	46.055	39.475	3.351	2.477
Accounts Payable	0.507	0.845	0.348	1.185	0.922
Payable/Accrued					0.038
Accrued Expenses	2.952	3.511	3.312	2.166	1.517
Notes Payable/Short Term Debt	0	0	0	0	0
Total Liabilities	4.688	47.52	41.168	3.409	2.477
Total Long Term Debt	0	0.016	0	0	0
Total Equity	40.033	32.605	32.986	65.015	89.429
Redeemable Preferred Stock					0
Common Stock	0.004	0.003	0.003	0.003	0.003
Additional Paid-In Capital	203.482	171.597	136.868	126.594	122.526
Retained Earnings (Accumulated Deficit)	-163.453	-138.966	-103.886	-61.192	-33.083
Total Liabilities & Shareholders’ Equity	44.721	80.125	74.154	68.424	91.906
Total Common Shares Outstanding	41.0941	27.5191	25.4411	25.807	25.7048
Property/Plant/Equipment, Total - Net	5.33	5.502	4.938	2.201	0.255
Other Long Term Assets, Total	0.276	0.295	1.566	1.24	0.499
Treasury Stock - Common		0	0	0	0
Short Term Investments	0	54.602	54.784	52.776	79.538
Property/Plant/Equipment, Total - Gross	6.029	5.756	5.065	2.285	0.275
Accumulated Depreciation, Total	-0.699	-0.254	-0.127	-0.084	-0.02
Other Equity, Total		-0.029	0.001	-0.39	-0.017
Other Liabilities, Total	1.229	1.449	1.693	0.058
Current Port. of LT Debt/Capital Leases	0	41.699	35.315
Other Current Liabilities, Total		0	0.5
Capital Lease Obligations	0	0.016
Total Receivables, Net	0.487
Long Term Debt	0

	Sep 2023	Jun 2023	Mar 2023	Dec 2022	Sep 2022
Total Current Assets	91.725	56.777	63.097	39.115	43.395
Cash and Short Term Investments	84.308	55.14	59.952	34.273	39.454
Cash & Equivalents	84.308	55.14	59.952	34.273	32.473
Short Term Investments				0	6.981
Total Receivables, Net	4.072	0.173	0.056	0.487	0.419
Prepaid Expenses	3.066	1.464	3.089	4.355	3.522
Total Assets	97.148	62.201	68.639	44.721	49.147
Property/Plant/Equipment, Total - Net	4.897	4.988	5.173	5.33	5.531
Property/Plant/Equipment, Total - Gross	5.941	5.953	6.003	6.029	6.1
Accumulated Depreciation, Total	-1.044	-0.965	-0.83	-0.699	-0.569
Other Long Term Assets, Total	0.526	0.436	0.369	0.276	0.221
Total Current Liabilities	11.374	5.731	2.643	3.459	3.078
Accounts Payable	1.925	2.057	0.575	0.507	0.137
Accrued Expenses	9.418	3.674	2.068	2.952	2.941
Notes Payable/Short Term Debt	0	0	0	0	0
Current Port. of LT Debt/Capital Leases	0.031			0	0
Other Current Liabilities, Total
Total Liabilities	54.845	6.801	3.793	4.688	4.382
Total Long Term Debt	42.482	0	0	0	0
Other Liabilities, Total	0.989	1.07	1.15	1.229	1.304
Total Equity	42.303	55.4	64.846	40.033	44.765
Common Stock	0.004	0.004	0.004	0.004	0.004
Additional Paid-In Capital	248.133	236.428	234.884	203.482	202.311
Retained Earnings (Accumulated Deficit)	-205.834	-181.032	-170.042	-163.453	-157.521
Treasury Stock - Common	0	0	0		0
Other Equity, Total					-0.029
Total Liabilities & Shareholders’ Equity	97.148	62.201	68.639	44.721	49.147
Total Common Shares Outstanding	42.0645	41.8521	41.8521	41.0941	41.0941
Capital Lease Obligations	0.081			0	0
Other Current Assets, Total
Accounts Receivable - Trade, Net	3.946
Total Inventory	0.279
Long Term Debt	42.401

Annual
Quarterly

	2022	2021	2020	2019	2018
Net income/Starting Line	-24.487	-35.08	-42.694	-28.207	-20.648
Cash From Operating Activities	-18.65	-27.582	-30.207	-27.408	-17.874
Non-Cash Items	7.183	7.789	10.809	2.463	1.816
Cash Interest Paid	1.789	2.85	1.875	0	0
Changes in Working Capital	-1.8	-0.535	1.635	-1.728	0.938
Cash From Financing Activities	-16.87	33.646	35.232	0.423	99.376
Financing Cash Flow Items	-0.017	0	0.319	0	-7.881
Issuance (Retirement) of Stock, Net	26.901	28.676	0.453	0.423	107.257
Net Change in Cash	18.521	5.066	1.445	-1.03	1.608
Cash From Operating Activities	0.454	0.244	0.043	0.064	0.02
Cash From Investing Activities	54.041	-0.998	-3.58	25.955	-79.894
Capital Expenditures	-0.302	-0.883	-1.47	-0.682	-0.275
Other Investing Cash Flow Items, Total	54.343	-0.115	-2.11	26.637	-79.619
Issuance (Retirement) of Debt, Net	-43.754	4.97	34.46

	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Net income/Starting Line	-6.589	-24.487	-18.555	-18.638	-8.47
Cash From Operating Activities	-4.59	-18.65	-13.696	-15.521	-8.34
Cash From Operating Activities	0.131	0.454	0.323	0.196	0.098
Non-Cash Items	1.165	7.183	5.92	3.228	1.725
Cash Interest Paid	0	1.789	1.788	1.468	0.725
Changes in Working Capital	0.703	-1.8	-1.384	-0.307	-1.693
Cash From Investing Activities	-0.011	54.041	47.287	45.218	43.013
Capital Expenditures	-0.011	-0.302	-0.236	-0.159	-0.005
Other Investing Cash Flow Items, Total	0	54.343	47.523	45.377	43.018
Cash From Financing Activities	30.28	-16.87	-16.87	-0.019	-0.018
Issuance (Retirement) of Stock, Net	30.308	26.901	26.901	0	0
Issuance (Retirement) of Debt, Net	0	-43.754	-43.754	-0.002	-0.001
Net Change in Cash	25.679	18.521	16.721	29.678	34.655
Financing Cash Flow Items	-0.028	-0.017	-0.017	-0.017	-0.017

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

1:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Verrica Pharmaceuticals Inc. Company profile

About Verrica Pharmaceuticals Inc

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing novel treatments for skin diseases. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through single-use precision applicator. The Company is developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a contagious and primarily pediatric viral skin disease, and common warts. It is conducting Phase II clinical trial for the treatment of plantar warts.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Verrica Pharmaceuticals Inc revenues increased from $0K to $12M. Net loss decreased 18% to $35.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-Based Compensation in SG&A decrease of 50% to $4.5M (expense), Research and development - Balancing val decrease of 3% to $14.4M (expense).

Industry:

Pharmaceuticals (NEC)

10 N High St Ste 200
WEST CHESTER
PENNSYLVANIA 19380-3014
US

Income Statement

Annual
Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024